

**RECEIVED
CENTRAL FAX CENTER**

NOV 09 2006

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

AMENDMENT UNDER 37 C.F.R. 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 13, 2006, please amend the above-identified application as follows:

Amendments to the claims are reflected in the listing of claims, which begins on page 3 of this document.

Remarks and arguments begin on page 5 of this document.

**RECEIVED
CENTRAL FAX CENTER**

NOV 09 2006

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schüleln et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner M. Rao, fax number (571) 273-8300.

Respectfully submitted,

Date: November 9, 2006


Julie Tabarovsky
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097